Coleman M - Search Results

1

The role of FDG-PET imaging in the management of lymphoma.

Kostakoglu L, Leonard JP, Coleman M, Goldsmith SJ. Kostakoglu L, et al. Among authors: coleman m. Clin Adv Hematol Oncol. 2004 Feb;2(2):115-21. Clin Adv Hematol Oncol. 2004. PMID: 16163171 Review.

2

Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.

Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Kostakoglu L, et al. Among authors: coleman m. Cancer. 2002 Feb 15;94(4):879-88. Cancer. 2002. PMID: 11920454 Free article. Clinical Trial.

3

PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. Kostakoglu L, et al. Among authors: coleman m. J Nucl Med. 2002 Aug;43(8):1018-27. J Nucl Med. 2002. PMID: 12163626 Free article.

4

Early 18F-labeled fluoro-2-deoxy-D-glucose positron emission tomography scanning in the lymphomas: changing the paradigms of treatments?

Coleman M, Kostakoglu L. Coleman M, et al. Cancer. 2006 Oct 1;107(7):1425-8. doi: 10.1002/cncr.22178. Cancer. 2006. PMID: 16933331 Free article.

5

FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.

Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, Chandramouly A, Verma S, Kothari P, Coleman M. Kostakoglu L, et al. Among authors: coleman m. Cancer. 2006 Dec 1;107(11):2678-87. doi: 10.1002/cncr.22276. Cancer. 2006. PMID: 17063502 Free article.

6

FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma.

Rutherford SC, Andemariam B, Philips SM, Elstrom RL, Chadburn A, Furman RR, Niesvizky R, Martin P, Fahey TJ, Coleman M, Goldsmith SJ, Leonard JP. Rutherford SC, et al. Among authors: coleman m. Leuk Lymphoma. 2008 Apr;49(4):719-26. doi: 10.1080/10428190801927387. Leuk Lymphoma. 2008. PMID: 18398739

7

Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma.

Elstrom RL, Leonard JP, Coleman M, Brown RK. Elstrom RL, et al. Among authors: coleman m. Ann Oncol. 2008 Oct;19(10):1770-3. doi: 10.1093/annonc/mdn282. Epub 2008 Jun 10. Ann Oncol. 2008. PMID: 18550578 Free PMC article.

8

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.

Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Cesano A, Goldenberg DM. Leonard JP, et al. Among authors: coleman m. J Clin Oncol. 2003 Aug 15;21(16):3051-9. doi: 10.1200/JCO.2003.01.082. Epub 2003 Jul 1. J Clin Oncol. 2003. PMID: 12837807 Clinical Trial.

9

CD22-directed monoclonal antibody therapy for lymphoma.

Siegel AB, Goldenberg DM, Cesano A, Coleman M, Leonard JP. Siegel AB, et al. Among authors: coleman m. Semin Oncol. 2003 Aug;30(4):457-64. doi: 10.1016/s0093-7754(03)00240-9. Semin Oncol. 2003. PMID: 12939714 Review.

10

Epratuzumab in non-Hodgkin's lymphomas.

Furman RR, Coleman M, Leonard JP. Furman RR, et al. Among authors: coleman m. Curr Treat Options Oncol. 2004 Aug;5(4):283-8. doi: 10.1007/s11864-004-0019-1. Curr Treat Options Oncol. 2004. PMID: 15233905 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,883 results

Search Page